Companies:
49,811
Total Market Cap:
139341154754882.51
Global Rank
#16691
Country Rank
#48
Market Cap
346.38 M
Price
6.44
Change (%)
1.82%
Volume
636,675
Prothena Corporation plc's latest marketcap:
346.38 M
As of 07/05/2025, Prothena Corporation plc's market capitalization has reached $346.38 M. According to our data, Prothena Corporation plc is the 16691th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 346.38 M |
| Revenue (ttm) | 137.94 M |
| Net Income (ttm) | -110,266,000 |
| Shares Out | 53.83 M |
| EPS (ttm) | -2.05 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/07/2025 |
Market Cap Chart
Data Updated: 07/05/2025
Prothena Corporation plc's yearly market capitalization.
Prothena Corporation plc has seen its market value grow from $129.6 M to $346.38 M since 2012, representing a total increase of 167.27% and an annual compound growth rate (CAGR) of 8.18%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $346.38 M | -53.52% | 16691 |
| 12/31/2024 | $745.3 M | -61.78% | 10431 |
| 12/29/2023 | $1.95 B | -33.09% | 5690 |
| 12/30/2022 | $2.91 B | 26.63% | 4112 |
| 12/31/2021 | $2.3 B | 380.02% | 5613 |
| 12/31/2020 | $479.5 M | -24.08% | 11806 |
| 12/31/2019 | $631.6 M | 53.82% | 8892 |
| 12/31/2018 | $410.6 M | -71.51% | 10111 |
| 12/29/2017 | $1.44 B | -15.04% | 5678 |
| 12/30/2016 | $1.7 B | -20.98% | 4436 |
Company Profile
About Prothena Corporation plc
Prothena Corporation plc is a late-stage clinical biotechnology company specializing in the discovery and development of novel therapies for diseases caused by protein dysregulation. Headquartered in Dublin, Ireland, the company was founded in 2012.
Key Product Pipeline
- Birtamimab – A humanized antibody in Phase 3 clinical trials for AL amyloidosis.
- Prasinezumab – A humanized monoclonal antibody in Phase 2b trials for Parkinson’s disease and other synucleinopathies.
- Coramitug – An investigational antibody in Phase 2 trials for transthyretin amyloidosis.
- BMS-986446 – An antibody in Phase 2 trials for Alzheimer’s disease.
- PRX012 – An investigational antibody in Phase 1 trials for Alzheimer’s disease.
- PRX123 – A Dual Aβ-Tau Vaccine in preclinical trials for Alzheimer’s disease.
- PRX019 – An investigational antibody in Phase 1 trials for neurodegenerative diseases.
Strategic Collaborations
Prothena has established key partnerships to advance its research:
- F. Hoffmann-La Roche Ltd. – License, development, and commercialization agreement for α-synuclein-targeting antibodies, including prasinezumab.
- Bristol Myers Squibb – Master collaboration agreement to develop antibodies targeting tau and TDP-43.
Frequently Asked Questions
-
What is Prothena Corporation plc's (PRTA) current market cap?As of 07/05/2025, Prothena Corporation plc (including the parent company, if applicable) has an estimated market capitalization of $346.38 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Prothena Corporation plc (PRTA) rank globally by market cap?Prothena Corporation plc global market capitalization ranking is approximately 16691 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.